Co-Diagnostics, Inc. (CODX) Return on equity 2017–2025
Co-Diagnostics, Inc. (CODX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-227.3%FY2025 · since FY2017: -180.7% → -227.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -227.3% | -157.5 pp |
| FY2024 | -69.9% | -28.6 pp |
| FY2023 | -41.3% | -28.9 pp |
| FY2022 | -12.4% | -39.7 pp |
| FY2021 | 27.3% | -36.4 pp |
| FY2020 | 63.7% | +420.3 pp |
| FY2019 | -356.6% | — |
| FY2017 | -180.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice